Agios Pharmaceuticals, Inc. (AGIO): Price and Financial Metrics
Today's Latest Price: $50.66 USD
Jun 5 4:00pm Add AGIO to Watchlist Sign Up POWR Components:
Buy & Hold Grade
Peer Grade Industry Rank AGIO Stock Summary Of note is the ratio of Agios Pharmaceuticals Inc's sales and general administrative expense to its total operating expenses; merely 13.23% of US stocks have a lower such ratio. AGIO's price/sales ratio is 19.54; that's higher than the P/S ratio of 93.17% of US stocks. As for revenue growth, note that AGIO's revenue has grown 50.87% over the past 12 months; that beats the revenue growth of 89.78% of US companies in our set. If you're looking for stocks that are quantitatively similar to Agios Pharmaceuticals Inc, a group of peers worth examining would be BPMC, RARE, DRNA, PRNB, and RGNX. Visit AGIO's SEC page to see the company's official filings. To visit the company's web site, go to www.agios.com. AGIO Price/Volume Stats
3.49B Agios Pharmaceuticals, Inc. (AGIO) Company Bio
Agios Pharmaceuticals is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic disorders of metabolism through scientific leadership in the field of cellular metabolism. The company was founded in 2007 and is based in Cambridge, Massachusetts.
AGIO Latest News Stream
All News Types Commentary Corp. News Cramer Debt Offering Downgrade Earnings Mgmt Change New Coverage (Bullish) New Coverage (Neutral) Product News PT Lowered PT Raised PT Set (Bullish) Rating Reiterated (Bullish) Rating Reiterated (Neutral) Stock Offering Upgrade
Event/Time News Detail Loading, please wait... Latest AGIO News From Around the Web
Below are the latest news stories about Agios Pharmaceuticals Inc that investors may wish to consider to help them evaluate AGIO as an investment opportunity.
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
– Vorasidenib Demonstrated Prolonged Disease Control and Encouraging Preliminary Activity with Median Progression-free Survival of 31.4 Months – – Vorasidenib Demonstrated a.
Agios Pharmaceuticals, Inc. (AGIO) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Is (AGIO) Outperforming Other Medical Stocks This Year?
– TIBSOVO® Is the First and Only IDH1 Inhibitor to Be Evaluated in a Phase 3 Clinical Trial for IDH1-Mutant Cholangiocarcinoma – CAMBRIDGE, Mass., May 19, 2020 -- Agios.
Read More 'AGIO' Stories Here
AGIO Price Returns
-42.06% Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Page generated in 0.9901 seconds.